January 17, 2017: Biogen announced today that it had signed a settlement and license deal with Forward Pharma with a $1.25B cash payment. The licensing agreement gives Biogen an irrevocable license to Forward’s intellectual property.
January 17, 2017: How could the federal government save money when it comes to providing treatments for hepatitis C. For Peter B. Bachand Mark Trusheim the answer is simple.
January 17, 2017: Merck ended 2016 hitting key milestones towards expanding its U.S. footprint in biomedical research, including inking a deal for the company’s future west coast discovery research center in SSF.
January 17, 2017: Could pharma giant BMS soon be an acquisition target. A recent stock purchase by activist investor Barry Rosenstein of Jana Partners may indicate such a plan. Writing in The Street, Ronald Orol said Jana Partners has “threatened proxy contests at nine companies...”